Jacqueline Jonklaas, Professor in the endocrinology division at Georgetown University, has submitted a paper entitled “Evidence-Based Use of Levothyroxine/Liothyronine Combinations in TreatingHypothyroidism”
Below are excerpts from a (2nd March, 2021) report in Medscape Medical News:
“Numerous trials have been conducted on short-acting liothyronine (LT3) in combination with the standard therapy of levothyroxine (LT4). However, the experts agreed that shortcomings in the existing studies and mounting unanswered questions need to be addressed, Jacqueline Jonklaas, MD, PhD, told Medscape Medical News“……………
“Patient-reported outcomes were acknowledged as essential in the full picture of understanding treatment efficacy, and the experts agreed that an emphasis on those outcomes will be important in any future trials of combination therapy.”
“Among the key topics agreed upon is the need to evaluate a sustained-release T3 preparation. Such a preparation could overcome concern of the dissipation of circulating T3 that occurs with oral tablet formulations, which fail to achieve the relatively stable levels seen in normal individuals, Jonklaas noted.”
“There was unanimous agreement that when and if a sustained-release T3 preparation became available and had undergone preliminary testing, new trials with such a preparation were definitely warranted,” she said. Preliminary testing of a new product that potentially provides sustained release of T3 has recently started.
WHAT THIS MEANS, TO YOU AND ME:
THIS MEANS that doctors have finally begun to listen what patients have been saying for the past many years: the accepted treatment of hypothyroidism using Ltroxin and Synthroid doesn’t work and the time has come to prescribe T3, or a combination of T3 and T4, instead.
So in a couple of years, the use of slow-release T3 will be accepted, the misery of millions who have been treated with T4 alone will come to an end and “the system” will authorise prescription of slow-release T3 as a “covered” medication.